(ACA) Arcosa - Ratings and Ratios
Aggregates, Wind Towers, Barges, Utility Structures, Trench Shields
Dividends
| Dividend Yield | 0.18% |
| Yield on Cost 5y | 0.38% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 96.4% |
| Payout Ratio | 5.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 27.7% |
| Value at Risk 5%th | 43.5% |
| Relative Tail Risk | -4.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.14 |
| Alpha | -11.64 |
| CAGR/Max DD | 0.74 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.395 |
| Beta | 1.091 |
| Beta Downside | 0.958 |
| Drawdowns 3y | |
|---|---|
| Max DD | 36.63% |
| Mean DD | 8.53% |
| Median DD | 5.41% |
Description: ACA Arcosa November 07, 2025
Arcosa, Inc. (NYSE: ACA) operates three core segments in the U.S. infrastructure space: Construction Products (aggregates, specialty materials, and site-support equipment), Engineered Structures (utility, wind-tower, traffic, lighting, and telecom structures sold to contractors, DOTs, and municipalities), and Transportation Products (inland barges, barge covers, winches, and marine hardware for commercial shippers and lessors). The company, incorporated in 2018 and headquartered in Dallas, Texas, focuses on serving both residential/commercial construction and large-scale public-sector projects.
Recent quarterly filings show ACA generated $1.02 billion in revenue, with the Construction Products segment contributing roughly 55% and delivering a segment EBIT margin of 9.8%, while Engineered Structures posted a 12.4% margin, reflecting higher pricing power in utility-scale wind and telecom projects. The business is highly sensitive to U.S. federal and state infrastructure spending; the bipartisan infrastructure law and upcoming DOT capital budgets are projected to boost demand for aggregates and utility structures by 4-6% YoY through 2027. Additionally, the transportation-equipment market benefits from rising domestic freight volumes, which have grown at a 3.2% annual rate over the past three years.
For a deeper, data-driven assessment of ACA’s valuation and risk profile, you may find ValueRay’s analytical tools useful for further exploration.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (148.6m TTM) > 0 and > 6% of Revenue (6% = 170.0m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 3.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 20.91% (prev 45.35%; Δ -24.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 469.3m > Net Income 148.6m (YES >=105%, WARN >=100%) |
| Net Debt (1.36b) to EBITDA (542.1m) ratio: 2.51 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.0m) change vs 12m ago 0.41% (target <= -2.0% for YES) |
| Gross Margin 21.61% (prev 19.84%; Δ 1.77pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 60.21% (prev 57.06%; Δ 3.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.65 (EBITDA TTM 542.1m / Interest Expense TTM 119.3m) >= 6 (WARN >= 3) |
Altman Z'' 2.17
| (A) 0.12 = (Total Current Assets 1.17b - Total Current Liabilities 579.7m) / Total Assets 5.05b |
| (B) 0.18 = Retained Earnings (Balance) 897.7m / Total Assets 5.05b |
| (C) 0.07 = EBIT TTM 315.8m / Avg Total Assets 4.70b |
| (D) 0.36 = Book Value of Equity 881.1m / Total Liabilities 2.47b |
| Total Rating: 2.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.18
| 1. Piotroski 6.50pt |
| 2. FCF Yield 4.76% |
| 3. FCF Margin 11.11% |
| 4. Debt/Equity 0.61 |
| 5. Debt/Ebitda 2.51 |
| 6. ROIC - WACC (= -1.67)% |
| 7. RoE 5.96% |
| 8. Rev. Trend 84.07% |
| 9. EPS Trend 49.43% |
What is the price of ACA shares?
Over the past week, the price has changed by +3.31%, over one month by +10.43%, over three months by +16.48% and over the past year by +2.86%.
Is ACA a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 119.8 | 8.1% |
| Analysts Target Price | 119.8 | 8.1% |
| ValueRay Target Price | 131.9 | 19% |
ACA Fundamental Data Overview December 10, 2025
P/E Trailing = 35.5648
P/E Forward = 19.2678
P/S = 1.8533
P/B = 2.0357
P/EG = 6.7234
Beta = 0.998
Revenue TTM = 2.83b USD
EBIT TTM = 315.8m USD
EBITDA TTM = 542.1m USD
Long Term Debt = 1.57b USD (from longTermDebt, last quarter)
Short Term Debt = 9.30m USD (from shortTermDebt, last quarter)
Debt = 1.58b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.36b USD (from netDebt column, last quarter)
Enterprise Value = 6.61b USD (5.25b + Debt 1.58b - CCE 220.0m)
Interest Coverage Ratio = 2.65 (Ebit TTM 315.8m / Interest Expense TTM 119.3m)
FCF Yield = 4.76% (FCF TTM 314.6m / Enterprise Value 6.61b)
FCF Margin = 11.11% (FCF TTM 314.6m / Revenue TTM 2.83b)
Net Margin = 5.25% (Net Income TTM 148.6m / Revenue TTM 2.83b)
Gross Margin = 21.61% ((Revenue TTM 2.83b - Cost of Revenue TTM 2.22b) / Revenue TTM)
Gross Margin QoQ = 24.05% (prev 22.54%)
Tobins Q-Ratio = 1.31 (Enterprise Value 6.61b / Total Assets 5.05b)
Interest Expense / Debt = 1.71% (Interest Expense 27.1m / Debt 1.58b)
Taxrate = 16.19% (14.1m / 87.1m)
NOPAT = 264.7m (EBIT 315.8m * (1 - 16.19%))
Current Ratio = 2.02 (Total Current Assets 1.17b / Total Current Liabilities 579.7m)
Debt / Equity = 0.61 (Debt 1.58b / totalStockholderEquity, last quarter 2.58b)
Debt / EBITDA = 2.51 (Net Debt 1.36b / EBITDA 542.1m)
Debt / FCF = 4.33 (Net Debt 1.36b / FCF TTM 314.6m)
Total Stockholder Equity = 2.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.94% (Net Income 148.6m / Total Assets 5.05b)
RoE = 5.96% (Net Income TTM 148.6m / Total Stockholder Equity 2.49b)
RoCE = 7.76% (EBIT 315.8m / Capital Employed (Equity 2.49b + L.T.Debt 1.57b))
RoIC = 6.37% (NOPAT 264.7m / Invested Capital 4.15b)
WACC = 8.04% (E(5.25b)/V(6.83b) * Re(10.03%) + D(1.58b)/V(6.83b) * Rd(1.71%) * (1-Tc(0.16)))
Discount Rate = 10.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.31%
[DCF Debug] Terminal Value 71.72% ; FCFE base≈237.1m ; Y1≈241.9m ; Y5≈267.2m
Fair Price DCF = 69.02 (DCF Value 3.38b / Shares Outstanding 49.0m; 5y FCF grow 1.84% → 3.0% )
EPS Correlation: 49.43 | EPS CAGR: 43.75% | SUE: 1.03 | # QB: 1
Revenue Correlation: 84.07 | Revenue CAGR: 11.99% | SUE: 0.78 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.53 | Chg30d=+0.012 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=4.85 | Chg30d=+0.256 | Revisions Net=+6 | Growth EPS=+14.5% | Growth Revenue=+6.0%
Additional Sources for ACA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle